451 related articles for article (PubMed ID: 21573959)
21. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
[TBL] [Abstract][Full Text] [Related]
22. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
23. Molecular biology of renal cell carcinoma.
Mellado B; Gascón P
Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
[TBL] [Abstract][Full Text] [Related]
24. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database.
Pal S; Gong J; Mhatre SK; Lin SW; Surinach A; Ogale S; Vohra R; Wallen H; George D
BMC Cancer; 2019 Jun; 19(1):548. PubMed ID: 31174493
[TBL] [Abstract][Full Text] [Related]
25. Advanced renal cell carcinoma: current and emerging management strategies.
Escudier B
Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
[TBL] [Abstract][Full Text] [Related]
26. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
Hutson TE; Sonpavde G; Galsky MD
Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
[TBL] [Abstract][Full Text] [Related]
27. Optimizing recent advances in metastatic renal cell carcinoma.
Courtney KD; Choueiri TK
Curr Oncol Rep; 2009 May; 11(3):218-26. PubMed ID: 19336014
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the treatment of metastatic renal cell carcinoma.
Abe H; Kamai T
Int J Urol; 2013 Oct; 20(10):944-55. PubMed ID: 23692504
[TBL] [Abstract][Full Text] [Related]
29. Signaling inhibitors in metastatic renal cell carcinoma.
Escudier B
Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
[TBL] [Abstract][Full Text] [Related]
30. Metastatic clear cell renal carcinoma - an unusual response to Temsirolimus in second line therapy.
Stanculeanu DL; Lazescu A; Zob DD; Bunghez R; Anghel R; Poteca TD
J Med Life; 2016; 9(2):193-8. PubMed ID: 27453754
[TBL] [Abstract][Full Text] [Related]
31. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
32. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.
Schmidinger M; Bellmunt J
Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917
[TBL] [Abstract][Full Text] [Related]
33. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
Rodríguez-Antona C; García-Donas J
Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
[TBL] [Abstract][Full Text] [Related]
34. Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application.
Nielsen OH; Grimm D; Wehland M; Bauer J; Magnusson NE
Curr Vasc Pharmacol; 2015; 13(3):381-91. PubMed ID: 24548189
[TBL] [Abstract][Full Text] [Related]
35. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
36. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Feinberg BA; Jolly P; Wang ST; Fortner B; Scott J; Gilmore J; Neary MP; Duh MS
Med Oncol; 2012 Jun; 29(2):786-94. PubMed ID: 21479699
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
38. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.
Fogli S; Porta C; Del Re M; Crucitta S; Gianfilippo G; Danesi R; Rini BI; Schmidinger M
Cancer Treat Rev; 2020 Mar; 84():101966. PubMed ID: 32044644
[TBL] [Abstract][Full Text] [Related]
39. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Rini BI
Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
[TBL] [Abstract][Full Text] [Related]
40. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Heng DY; Mackenzie MJ; Vaishampayan UN; Bjarnason GA; Knox JJ; Tan MH; Wood L; Wang Y; Kollmannsberger C; North S; Donskov F; Rini BI; Choueiri TK
Ann Oncol; 2012 Jun; 23(6):1549-55. PubMed ID: 22056973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
